Skip to main content

Table 1 Clinicopathologic features of CRC patients by tumor location

From: A novel DNA methylation panel accurately detects colorectal cancer independently of molecular pathway

Characteristic Total (n = 214) Colon (n = 110) Rectum (n = 104)
Age (years) mean (range) 60.35 (25–80) 60.82 (25–80) 59.80 (31–80)
Gender
 Female 74 (34.6%) 42 (38.2%) 32 (30.8%)
 Male 140 (65.4%) 68 (61.8%) 72 (69.2%)
Stage
 I/II 52 (24.3%) 24 (21.8%) 28 (26.9%)
 III 52 (24.3%) 20 (18.2%) 32 (30.8%)
 IV 108 (50.5%) 64 (58.2%) 44 (42.3%)
 Unknown 2 (0.9%) 2 (1.8%)
Tumor differentiation
 Well 4 (1.9%) 1 (0.9%) 3 (2.9%)
 Moderate 123 (57.5%) 79 (71.8%) 44 (42.3%)
 Poor 5 (2.3%) 4 (3.6%) 1 (1.0%)
 Not assessable 82 (38.3%) 26 (23.6%) 56 (53.8%)
KRAS mutation status
 Wildtype 116 (54.2%) 60 (54.5%) 56 (53.9%)
 Mutated 84 (39.3%) 46 (41.8%) 38 (36.5%)
 Not available 14 (6.5%) 4 (3.6%) 10 (9.6%)
MSI
 MSI-H 8 (3.7%) 8 (7.3%) 0 (0%)
 MSI-L/MSS 206 (96.3%) 102 (92.7%) 104 (100%)
CIMP
 CIMP-positive 18 (8.5%) 6 (5.6%) 12 (11.5%)
 CIMP-negative 193 (91.5%) 101 (94.4%) 92 (88.5%)
Neoadjuvant treatment
 Yes 69 (32.2%) 16 (14.5%) 53 (51.0%)
 No 145 (67.8%) 94 (85.5%) 51 (49.0%)
Adjuvant treatment
 Yes 171 (80.0%) 89 (80.9%) 82 (78.8%)
 No 45 (20.0%) 21 (19.1%) 22 (21.2%)
  1. CIMP CpG island methylator phenotype, MSI microsatellite instability, MSI-H MSI high, MSI-L MSI low, MSS microsatellite stable
\